Canagliflozin
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for accurate information.
Canagliflozin Product Information
Canagliflozin is listed under API and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Canagliflozin. The product is supplied by Clearsynth under CAT No. CS-O-10825.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Canagliflozin
CAS No.
842133-18-0
CAT No.
CS-O-10825
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C24H25FO5S
Molecular Weight
444.52
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for accurate information.
Description
Regulatory Description
Canagliflozin is supplied with detailed characterization data compliant with regulatory guideline. Canagliflozin can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Canagliflozin.
Overview
Canagliflozin belongs to a new class of anti-diabetic drugs that works by inhibiting the sodium-glucose transport protein (SGLT2). This transport protein is found in the kidney and is responsible for reabsorbing glucose that has been filtered.
Synonyms
Canagliflozin
Application Notes
Canagliflozin belongs to a new class of anti-diabetic drugs that works by inhibiting the sodium-glucose transport protein (SGLT2). This transport protein is found in the kidney and is responsible for reabsorbing glucose that has been filtered.
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.